News | July 04, 2021
Kwality Pharmaceuticals Q4FY21 consolidated PAT higher at Rs. 8.14 Cr
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company reported total income of Rs.263.60 crores during the 12 months period ended March 31, 2021
The company has posted net profit of Rs.1.09 crores for the 12 months period ended March 31, 2021
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
The company has reported total income of Rs.355.43 crores during FY 2020-21
The company has now received the renewed GMP (Good Manufacturing Practices) certificate thereby confirming the successful closure of the inspection
The agreements between the parties involve a total fee of Rs. 8 lakh plus taxes for the grant of the licenses on a non-exclusive basis to SPL
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
Broadens company’s oncology platform of Targeted Alpha Therapies (TATs)
Sun Pharma is granted rights for co-marketing of the drug in India in the private market under the brand name CARITEC
The Banzel Tablets, 200 mg and 400 mg market2 achieved annual sales of approximately $285.3 million.
Subscribe To Our Newsletter & Stay Updated
